When assessing new techniques for use with marginalized populations, it is critical to consider costs and benefits free of unexamined biases. Anything less is discriminatory and unjust.
Malaria, HIV and tuberculosis rage as perpetual epidemics in developing nations. Developed nations have an ethical duty and compelling socioeconomic reasons for combatting these global infectious diseases.